

*Review Article*  
**Efficacy and Safety of Lebrikizumab in Atopic Dermatitis: A  
Systematic Review and Meta-Analysis**

---

**Abstract**

**Background:** Atopic Dermatitis (AD) is a long-lasting dermatological condition that leads to skin irritation and inflammation. In cases of severe cases of AD biological therapy may be warranted. In this systematic review and meta-analysis, we aim to assess the efficacy and safety of Lebrikizumab, an IL-13 immunomodulator.

**Methodology:** A systematic search was used in the following databases Medline, Scopus, Clinical Trials.gov registry (CT.gov), EBSCO, Science Direct, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar. The efficacy of Lebrikizumab was evaluated by using some measures such as Investigator's Global Assessment (IGA), Body Surface Area (BSA), and Eczema Area and Severity Index (EASI). The measures namely serious adverse events (SAEs), and non-serious adverse events (NSAEs) were used to assess the safety. The risk of bias was determined by the Revised Cochrane risk of bias tool.

**Results:** Four randomized controlled trials (RCTs) were included in our meta-analysis with a total of 1,686 patients who had taken lebrikizumab (n=1,168) compared with placebo (n= 518). The total analysis demonstrated a decrease in the area and severity of eczema as measured by EASI when using lebrikizumab, this decrease was statistically significant compared to placebo (mean difference (MD): -25.60, 95% CI [-38.01, -13.18],  $P < 0.0001$ ), statistically significant enhancement in the Change of BSA with lebrikizumab compared to placebo (MD: -9.81, 95% CI [-15.39, -4.23],  $P < 0.0006$ ), and significant enhancement in the EASI 75 score with lebrikizumab compared to placebo (Risk Ratio (RR):2.60, 95% CI [2.17, 3.13],  $P < 0.00001$ ). Lebrikizumab did not correlate significantly with the incidence of NSAEs and SAEs as concluded by the pooled analysis of safety.

**Conclusion:** Lebrikizumab has demonstrated promise as a treatment option for AD. It has shown significant effectiveness across various measures and has exhibited a favourable safety profile. Future research is required to evaluate long-term safety and efficacy.

**Systematic review registration:** CRD42024456389.

**Keywords:** Atopic dermatitis, Eczema, Lebrikizumab, anti-IL-13

## **Introduction**

Atopic Dermatitis (AD) is a long-lasting dermatological condition that leads to skin irritation and inflammation (1,5). AD affects both children and adults but is more common in children usually occurring between the ages of 3 to 6 months (1). The incidence of AD has increased through the years, affecting 15-20 % of the pediatric population and 1-3 % of adults (1,2). AD is a complex disease with various factors contributing to its pathophysiology. The exact cause of AD is not fully understood but a combination of genetic, immunological, microbial, and environmental factors is associated with AD development. The inside-out hypothesis suggests that cutaneous inflammation occurs before barrier impairment in AD. Inflammatory conditions weaken the skin's barrier by reducing the production of a protein called filaggrin, which is crucial for maintaining skin integrity. This disruption of the barrier can enable allergens and bacteria to penetrate the skin, leading to the development of AD. On the other hand, the outside-in hypothesis proposes that the impaired skin barrier precedes AD and is necessary for immune dysregulation to occur. When the skin barrier is disrupted, it can result in heightened immune responses, specifically Th2 responses, which contribute to inflammation in AD. Other factors, including genetic variations and environmental influences, may contribute to the development of AD in individuals without filaggrin mutations (1,3).

AD may result from the downregulation or mutation of the filaggrin (FLG) gene, which is necessary for healthy skin barrier function as it encodes the protein filaggrin, which is responsible for making a strong barrier matrix and may increase the skin's susceptibility to immunological dysregulation (1,4). Genetic factors and family history of atopic diseases such as asthma and allergic rhinitis, are important risk factors for developing atopic dermatitis (1). Immune dysfunction in AD is biphasic. In the acute phase, TH2 immune response is dominant while TH1 is dominant in the chronic phase (2,5). Moreover, environmental factors like allergens, pollutants, and irritants may also trigger atopic dermatitis symptoms (2). Current management of AD consists of avoidance of triggers, emollients, topical corticosteroids,

topical calcineurin inhibitors, and phosphodiesterase-4 inhibitors. In severe cases, oral corticosteroids, immunosuppressants, and biological agents may be used (6,19,20).

Lebrikizumab is an IgG4 monoclonal antibody targeting IL-13 and inhibiting the formation of IL-13Ra1 (IL-13 receptor alpha 1)/IL-4Ra (IL-4 receptor alpha) receptor complex. IL-13 plays a vital role in provoking inflammation and causing dysfunction of the skin barrier in atopic dermatitis (7–9). This induces the symptoms of AD to appear such as redness, itching, and skin thickening. IL-13 is produced by many different cells such as TH2 cells, eosinophils, and mast cells in response to triggers. Therefore, lebrikizumab downregulates the signaling pathway and the effects of IL-13 which are an important contributor to the disease pathogenesis. It can be used for treating adults and patients older than 12 with moderate to severe atopic dermatitis. (9). It's used in individuals who are candidates for systemic therapy due to the non-effectiveness of the topical treatments. The most common side effects include conjunctivitis and injection site reaction (7,8).

## **Materials and methods:**

Our study was registered before a preliminary search in alignment with PROSPERO . It utilized the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) checklist.

### **Eligibility criteria**

Our study included all patients who were treated with lebrikizumab for atopic dermatitis as monotherapy or in combination with other treatment modalities. We excluded all studies discussing treatments of atopic dermatitis other than lebrikizumab, Alternative uses of lebrikizumab other than atopic dermatitis treatment, irrelevant articles, and non-English articles.

### **Search strategy**

We systematically searched Medline, Scopus, Clinical Trials.gov registry (CT.gov), EBSCO, Science Direct, Cochrane Central Register of Controlled Trials (CENTRAL), and Google Scholar databases without any restriction on date or language. References of the included RCTs were inspected for relevant RCTs that were missed during the systematic search process. The search was conducted by using the keywords “Atopic dermatitis”, “Eczema”, “Lebrikizumab”, “Efficacy”, and “safety”.

## **Study selection and data extraction**

Two reviewers independently performed title and abstract screening by using Rayyan, full-text screening, and data extraction of RCTs that matched the eligibility criteria. Any conflict was resolved third author's opinion. Cochrane Risk of Bias Tool 1 was used to assess the included studies.

## **Results**

### **Literature Search Results**

A total of 227 articles had been selected for title and abstract screening. Following this initial screening process, only five articles were found to meet the specific criteria set for our study. These five articles were then subjected to a full screening process. To visualize the flow of the study selection process PRISMA flowchart (Figure 1).

### **Characteristics of the Included Studies**

Four studies were included in our meta-analysis NCT04250337, NCT04146363, NCT04178967, and NCT03443024, with a total of 1,686 patients who had taken lebrikizumab for atopic dermatitis compared with placebo (lebrikizumab group n =1,168 and placebo group n= 518). A summary of the included studies and baseline characteristics of the participants is provided in Table (1) and Table (2), respectively.

### **Risk of Bias Assessment**

By using the Cochrane risk of bias tool of RCT two reviewers did the risk of bias assessment independently reviewed and rated if the study was high risk or not, all trials were low risk of bias. Figure 2 & figure 3

### **Change in Eczema Area and Severity Index (EASI)**

The total analysis demonstrated a statistically significant improvement in the Change of EASI with lebrikizumab compared to placebo (mean difference (MD): -25.60, 95% CI [-38.01, -13.18],  $P < 0.0001$ ) (Figure 4). Lebrikizumab at 250mg Q2W showed a statistically significant

improvement in the Change of EASI compared to placebo (MD: -34.86, 95% CI [-41.45, -28.27],  $P < 0.00001$ ). Pooled studies showed no heterogeneity ( $P = 0.63$ ;  $I^2 = 0\%$ ).

Lebrikizumab at 250mg Q4W showed a statistically significant improvement in the Change of EASI compared to placebo (MD: -28.09, 95% CI [-46.31, -9.87],  $P = 0.003$ ).

Lebrikizumab at 125mg Q4W showed no significant difference between the two groups (MD: -10.41, 95% CI [-28.31, 7.48],  $P = 0.25$ ). Pooled studies demonstrated heterogeneity ( $P = 0.09$ ;  $I^2 = 66\%$ ).

### **Change in body surface area (BSA)**

The total analysis demonstrated a statistically significant improvement in the Change of BSA with lebrikizumab compared to placebo (MD: -9.81, 95% CI [-15.39, -4.23],  $P < 0.0006$ ) (Figure 5)

Lebrikizumab at 250mg Q2W showed a statistically significant improvement in the Change of BSA compared to placebo (MD: -14.74, 95% CI [-19.82, -9.65],  $P < 0.00001$ ). Pooled studies demonstrated heterogeneity ( $P = 0.02$ ;  $I^2 = 74\%$ ). A sensitivity analysis was conducted, and the heterogeneity was best resolved by excluding the yassky 2020 study ( $I^2 = 0\%$ ,  $P = 0.32$ ) (Figure 6).

Lebrikizumab at 250mg Q4W showed a statistically significant improvement in the Change of BSA compared to placebo (MD: -7.50, 95% CI [-14.61, -0.39],  $P = 0.04$ ).

Lebrikizumab at 125mg Q4W showed no significant difference between the two groups (MD: -2.51, 95% CI [-8.25, 3.23],  $P = 0.39$ ). Pooled studies showed no heterogeneity ( $P = 0.88$ ;  $I^2 = 0\%$ ).

### **Eczema Area and Severity Index (EASI 75) score**

The total analysis demonstrated a statistically significant improvement in the EASI 75 score with lebrikizumab compared to placebo (Risk Ratio (RR): 2.60, 95% CI [2.17, 3.13],  $P < 0.00001$ ) (Figure 7).

Lebrikizumab at 250mg Q2W showed a statistically significant improvement in the EASI 75 score compared to placebo (RR: 3.02, 95% CI [2.39, 3.82],  $P < 0.00001$ ). Pooled studies showed no heterogeneity ( $P = 0.38$ ;  $I^2 = 0\%$ ).

Lebrikizumab at 250mg Q4W showed a statistically significant improvement in the EASI 75 score compared to placebo (RR: 2.25, 95% CI [1.35, 3.74],  $P < 0.002$ ).

Lebrikizumab at 125mg Q4W showed a statistically significant improvement in the EASI 75 score compared to placebo (RR: 1.74, 95% CI [1.23, 2.45],  $P < 0.002$ ). Pooled studies showed no heterogeneity ( $P = 0.91$ ;  $I^2 = 0\%$ ).

### **Investigator's Global Assessment (IGA) score**

The total analysis demonstrated a statistically significant improvement in the IGA score with lebrikizumab compared to placebo (RR:2.71, 95% CI [2.13, 3.45],  $P < 0.00001$ ) (Figure 8).

Lebrikizumab at 250mg Q2W showed a statistically significant improvement in the IGA score compared to placebo (RR: 3.14, 95% CI [2.32, 4.23],  $P < 0.00001$ ). Pooled studies showed no heterogeneity ( $P = 0.92$ ;  $I^2 = 0\%$ ).

Lebrikizumab at 250mg Q4W showed a statistically significant improvement in the IGA score compared to placebo (RR: 2.19, 95% CI [1.08, 4.45],  $P < 0.03$ ).

Lebrikizumab at 125mg Q4W showed a statistically significant improvement in the IGA score compared to placebo (RR: 1.75, 95% CI [1.06, 2.89],  $P < 0.03$ ). Pooled studies showed no heterogeneity ( $P = 0.90$ ;  $I^2 = 0\%$ ).

### **Non-serious adverse events (NSAEs)**

The total analysis demonstrated no statistical difference in the incidence of NSAEs with lebrikizumab compared to placebo (RR:0.92, 95% CI [0.83, 1.02],  $P = 0.12$ ) (Figure 9).

Lebrikizumab at 250mg Q2W showed no statistical difference in the incidence of NSAEs compared to placebo (RR: 0.89, 95% CI [0.79, 1.00],  $P = 0.05$ ). Pooled studies showed heterogeneity ( $P = 0.05$ ;  $I^2 = 67\%$ ). A sensitivity analysis was conducted, and the heterogeneity was best resolved by excluding the yassky 2020 study ( $I^2 = 0\%$ ,  $P = 0.56$ ) (Figure 10).

Lebrikizumab at 250mg Q4W showed no statistical difference in the incidence of NSAEs compared to placebo (RR: 1.06, 95% CI [0.73, 1.53],  $P < 0.77$ ).

Lebrikizumab at 125mg Q4W showed no statistical difference in the incidence of NSAEs compared to placebo (RR: 1.00, 95% CI [0.78, 1.28],  $P = 0.98$ ). Pooled studies showed heterogeneity ( $P = 0.10$ ;  $I^2 = 63\%$ ).

### **Serious adverse events (SAEs)**

The total analysis demonstrated no statistical difference in the incidence of SAEs with lebrikizumab compared to placebo (RR:0.68, 95% CI [0.33, 1.42],  $P = 0.30$ ) (Figure 11).

Lebrikizumab at 250mg Q2W showed no statistical difference in the incidence of SAEs compared to placebo (RR:0.77, 95% CI [0.30, 2.03],  $P = 0.60$ ). Pooled studies showed no heterogeneity ( $P = 0.19$ ;  $I^2 = 39\%$ ).

Lebrikizumab at 250mg Q4W showed no statistical difference in the incidence of SAEs compared to placebo (RR: 0.13, 95% CI [0.01, 2.67],  $P < 0.19$ ). Lebrikizumab at 125mg Q4W showed no statistical difference in the incidence of SAEs compared to placebo (RR: 0.87, 95% CI [0.22, 3.37],  $P = 0.84$ ). Pooled studies showed no heterogeneity ( $P = 0.77$ ;  $I^2 = 0\%$ ).

## Discussion

AD presents with diverse signs and symptoms, influenced by many factors such as age, ethnicity, and socioeconomic status (10). Pruritus is the most reported symptom among patients with AD (11). Pruritus in AD is predominantly mediated by cytokines, such as interleukin-13 (IL-13) via stimulation of peripheral sensory neurons, rather than histamine-driven mechanisms (12). IL-13 has also been implicated in the impairment of epidermal barrier function, skin thickening, and recruitment of inflammatory cells (13).

The goals of treatment in patients with AD are to reduce inflammation, preserve the skin barrier function, alleviate skin dryness and pruritus, and prevent superinfections and flares. The current guidelines continue to recommend corticosteroids as a first-line treatment for moderate-to-severe AD (14). Because of the adverse effects of topical corticosteroids and patients' fears about using corticosteroids which may affect their compliance with treatment, investigation of alternative treatments is crucial for patients (15,16). Considering the significant influence of IL-13 on the development and progression of AD, the efficacy and safety of IL-13 inhibitors in the treatment of AD are recommended for evaluation. The first IL-13 inhibitor to receive FDA approval is Tralokinumab (17). Studies have shown that Tralokinumab is effective and safe in treating AD (18).

In this systematic review and meta-analysis, four clinical trials with a cumulative sample size of 1,686 patients were enrolled to evaluate the efficacy and safety of lebrikizumab as a monotherapy for the management of atopic dermatitis. We found that treatment with lebrikizumab, compared to a placebo, significantly improves all the evaluated parameters of moderate to severe AD, including Eczema Area and Severity Index (EASI), Body Surface Area (BSA), Eczema Area and Severity Index (EASI 75), and Investigator's Global Assessment (IGA) scores. Regarding safety, we found that there is no difference in the incidence of serious adverse events (SAEs) and non-serious adverse events (NSAEs) between the placebo group and the treatment group receiving lebrikizumab.

This review paper was done using different databases and tools, for example, Clinical Trials, Ovid, ScienceDirect, Google Scholar, and PubMed to find as many qualified studies as possible

and to narrow down the spectrum of studies used to only the studies that meet the detailed criteria that the study researchers set for this paper by using Cochrane, this process has made this review study more depersonalized of the researchers' biases which made the results more reliable. Due to the methods mentioned above for the selection criteria and the novelty of Lebrikizumab, it was challenging to find a lot of studies due to the low number of RCTs. Study limitations encompassed the exclusion of pediatric age groups, focusing instead on the young and elderly cohorts. For instance, in [Eric L. Simpson], the trial enrolled 211 participants with moderate to severe AD aged  $\geq 12$  to  $< 18$ , spanning a 16-week duration. Conversely, [Jonathan I. Silverberg] followed a group aged 12 to  $> 18$  for 52 weeks, highlighting the potential age-dependent effects of Lebrikizumab. Additionally, the short treatment duration, typically lasting a few months in both placebo and treatment arms, such as in [Emma Gutman-Yassky] (16 weeks), may preclude the comprehensive evaluation of long-term efficacy and safety, as observed in [Eric L. Simpson] (52 weeks). Despite these limitations, efforts were made to mitigate biases and ensure the study's accuracy.

In summary of the aforementioned points, lebrikizumab has demonstrated promise as a treatment option for AD. It has shown significant effectiveness across various measures and has exhibited a favourable safety profile. However, there is a need for real-world experience studies and additional trials to evaluate lebrikizumab in comparison to other treatment options as well as evaluating it for long-term safety and efficacy.

## Conclusion

Amongst 227 articles, these four studies met the criteria for lebrikizumab's efficacy and safety in treating atopic dermatitis. The analysis of 1,686 patients provided compelling evidence supporting lebrikizumab's efficacy in improving both the EASI and IGA score compared to placebo. Lebrikizumab achieved significant results in the EASI 75 response rate, demonstrating a clinical improvement. All trials had a low risk of bias, sustaining the findings' robustness, as assessed using the Cochrane risk of bias tool. Moreover, the analysis clarified dose-dependent effects, with lebrikizumab at 250mg administered every two weeks exhibiting the most therapeutic benefits across various efficacy parameters. Conversely, the 125mg dose administered every four weeks failed to consistently demonstrate statistically significant

differences from their placebo, suggesting a potential dose-response relationship. Evaluation of adverse events showed no significant disparities between lebrikizumab and placebo in the incidence of NSAEs or SAEs, underscoring lebrikizumab's safety profile. Despite the methodological strengths of the examined studies, as evidenced by non-significant heterogeneity tests, and the absence of publication bias by Egger's test, the analysis suggests that the effect size estimate suggests no significant difference between treatment and control groups. Hedge's mean effect size estimate of -0.7 (95% CI, -0.183 to 0.042) corresponds to a low-level negative effect, as per Cohen's classification, and was statistically non-significant ( $P < 0.218$ ). These findings imply that the intervention under investigation does not yield a clear therapeutic benefit compared to the control condition. Although these studies demonstrate a systematic approach, the effectiveness of the treatment appears limited by the effect size analysis. These findings highlight the therapeutic potential of lebrikizumab, particularly at higher dosages and more frequent intervals. The results may impact treatment plans by providing information for treating atopic dermatitis. This points to directions for further research, such as finding the best dosage schedules to optimize therapeutic results while reducing adverse reactions, and the refinement of study methodologies. Future research is required to evaluate long-term safety and efficacy.




Figure 1 Study flowchart as per PRISMA criteria

UNDETERMINED

placebo

Table 1b  
Baseline data characteristics

Study name	Year	Clinical identifier	Control group			Treatment group			Treatment dosage / frequency	duration	results
			No. of participants male	severity of AD (EASI) Mean (SD)	Race (%)	No. of participants male	severity of AD (EASI) Mean (SD)	Race (%)			
Simpson, Eric L. / 2023	2023	NCT04250337	66/33	26.4 (10.6)	Asian(19.7), Black/African American(13.6), White(60.6)	145/75	27.7 (11.1)	Asian(12.4), Black/African American(13.1), White(62.1)	19.9	16 week	The study showed that lebrikizumab combined with topical corticosteroids (TCS) significantly improved skin clearance in patients with atopic dermatitis, and 75% improvement in the Eczema Area and Severity Index (EASI-75). The treatment also led to improvements in secondary endpoints and most adverse events were mild or moderate.
Silverberg 2023 (Advocate1)	2023	NCT04146363	141/68	31(12.9)	White (66), Asian (22), Black (11.3)	283/142	28.8(11.3)	White (69.3), Asian (13.8), Black (11.7),	36.1	52 week	Lebrikizumab therapy showed significant improvements in primary and secondary outcomes, including skin clearance, itch, and sleep disturbance, as early as week 2. It demonstrated a rapid onset of action in various aspects of atopic dermatitis.
Silverberg 2023 (Advocate2)	2023	NCT04178967	146/71	29.6 (10.8)	White (58.2), Asian (30.1), Black (6.8), Other (4.8)	281/145	29.7 (12)	White (59.8), Asian (27.8), Black (8.9), Other (3.6)	36.6	52 week	Lebrikizumab therapy demonstrated significant improvements in skin clearance, itch, and sleep interference compared to placebo at week 16, indicating rapid effectiveness in treating multiple aspects of the disease.
Emma Gutman-Yasky / 2020	2020	NCT03443024	52/28	28.9(11.8)	White (50.0), Black or African American(30.8), American Indian or Alaskan native(0), Asian(11.5), other(7.7)	73/27	29.9(13.5)	White(50.7), Black or African American(35.6), American Indian or Alaskan native(1.4), Asian(11.0), other(1.4)	16.5	16 week	The primary endpoint was the percentage change in Eczema Area and Severity Index (EASI) from baseline to week 16. Secondary endpoints included various improvements in EASI, Investigator's Global Assessment, and pruritus numeric rating scale scores, as well as monitoring of treatment-emergent adverse events.
						80/33	26.2 (10.1)	White(52.5), Black or African American(35.0), American Indian or Alaskan native(1.3), Asian(8.8), other(2.5)	17.9		
			75/26	25.5 (11.2)	White(53.3), Black or African American(30.7), American Indian or Alaskan native(1.3), Asian(8.0), other(6.7)			17.4	16 weeks		

study ID	lebrikizumab	placebo
----------	--------------	---------

	Change in Body Surface Area (BSA)							
	250mg Q2W		125mgQ4W		250mg Q4W		mean	SD
	mean	SD	mean	SD	mean	SD		
Silverberg 2023 (ADvocate1)	-30.23	20.12	--	--	--	--	-11.77	16.28
Silverberg 2023 (ADvocate2)	-29.65	19.22	--	--	--	--	-13.76	16.9
Simpson 2018	--	--	-9.3	27	--	--	-6.2	23.2
Yassky 2020	-24.3	21	-19.6	19.08	-24.9	20.08	-17.4	20.56

Table 2 The summary of included studies, change in Eczema Area and Severity (EASI)

	Change in Eczema Area and Severity Index (EASI)								
	250mg Q2W		125mgQ4W		250mg Q4W		mean	SD	
	mean	SD	mean	SD	mean	SD			
Silverberg 2023 (ADvocate1)	-64.75	53.26	--	--	--	--	-26.16	48.08	
Silverberg 2023 (ADvocate2)	-60.61	54.78	--	--	--	--	-28.22	46.8	
Simpson 2018	--	--	-9.1	22.7	--	--	-6.4	32.2	
Yassky 2020	-72.09	37.229	-62.34	37.266	-69.21	38.282	-41.12	59.496	

Table 3 The summary of included studies, Change in Body Surface Area (BSA)

study ID	lebrikizumab						placebo	
	Eczema Area and Severity Index (EASI75I) score							
	250mg Q2W		125mgQ4W		250mg Q4W		event	total
	event	total	event	total	event	total		
Silverberg 2023 (ADvocate1)	168	283	--	--	--	--	23	141
Silverberg 2023 (ADvocate2)	143	281	--	--	--	--	27	146
Simpson 2018	--	--	30	50	--	--	18	53
Yassky 2020	45	75	31	73	45	80	13	52

Table 4 The summary of included studies, Eczema Area and Severity Index (EASI75I) score

study ID	lebrikizumab						placebo	
	Investigator's Global Assessment (IGA) score							
	250mg Q2W		125mgQ4W		250mg Q4W		event	total
	event	total	event	total	event	total		
Silverberg 2023 (ADvocate1)	121	283	--	--	--	--	18	141
Silverberg 2023 (ADvocate2)	93	281	--	--	--	--	16	146
Simpson 2018	--	--	17	50	--	--	10	53
Yassky 2020	33	75	19	73	27	80	8	52

Table 5 The summary of included studies, Investigators Global Assessment (IGA)

study ID	lebrikizumab						placebo	
	non-serious adverse events (NSAEs)							
	250mg Q2W		125mgQ4W		250mg Q4W		event	total
	event	total	event	total	event	total		
Silverberg 2023 (ADvocate1)	126	283	--	--	--	--	72	141
Silverberg 2023 (ADvocate2)	155	295	--	--	--	--	97	149
Simpson 2018	--	--	25	50	--	--	33	53
Yassky 2020	45	75	41	73	39	80	24	52

Table 6 The summary of included studies, non-serious adverse events (NSAEs)

study ID	lebrikizumab						placebo	
	serious adverse events (SAEs)							
	250mg Q2W		125mgQ4W		250mg Q4W		event	total
	event	total	event	total	event	total		
Silverberg 2023 (ADvocate1)	6	283	--	--	--	--	1	141
Silverberg 2023 (ADvocate2)	2	295	--	--	--	--	4	149
Simpson 2018	--	--	2	50	--	--	2	53
Yassky 2020	2	75	2	73	0	80	2	52

Table 7 The summary of included studies, serious adverse events (SAEs)




Figure 2 Risk of bias graph

	Vassily 2017	Simpson, Eric 2022	Silverberg 2022	Silverberg 2023	
Random sequence generation (selection bias)	+	+	+	+	
Allocation concealment (selection bias)	+	+	+	+	
Blinding of participants and personnel (performance bias)	+	+	+	+	
Blinding of outcome assessment (detection bias)	+	+	+	+	
Incomplete outcome data (attrition bias)			+	+	
Selective reporting (reporting bias)		+	+	+	
Other bias		+		+	

Figure 3 Risk of bias summary.




Figure 4 Change in EASI




Figure 5 Change in BSA




Figure 6 Leave-one meta-analysis of change in BSA




Figure 7 EASI 75 score




Figure 8 IGA score




Figure 9 non-serious adverse events (NSAEs)




Figure 10 leave-one meta-analysis of NSAEs

## References

1. Avena-Woods C. Overview of atopic dermatitis. Am J Manag Care. 2017;23(8 Suppl):S115–23.
2. Nutten S. Atopic Dermatitis: Global Epidemiology and Risk Factors. Ann NutrMetab. 2015;66(Suppl. 1):8–16.
3. Silverberg NB, Silverberg JI. Inside Out or Outside In: Does Atopic Dermatitis Disrupt Barrier Function or Does Disruption of Barrier Function Trigger Atopic Dermatitis?
4. Weidinger S, Novak N. Atopic dermatitis. The Lancet. 2016 Mar;387(10023):1109–22.
5. Yang G, Seok JK, Kang HC, Cho YY, Lee HS, Lee JY. Skin Barrier Abnormalities and Immune Dysfunction in Atopic Dermatitis. Int J Mol Sci. 2020 Apr 20;21(8):2867.

6. Frazier W, Bhardwaj N. Atopic Dermatitis: Diagnosis and Treatment. *ATOPIIC Dermat.* 2020;101(10).
7. Guttman-Yassky E, Blauvelt A, Eichenfield LF, Paller AS, Armstrong AW, Drew J, et al. Efficacy and Safety of Lebrikizumab, a High-Affinity Interleukin 13 Inhibitor, in Adults with Moderate to Severe Atopic Dermatitis: A Phase 2b Randomized Clinical Trial. *JAMA Dermatol.* 2020 Apr 1;156(4):411–20.
8. Stein Gold L, Thaçi D, Thyssen JP, Gooderham M, Laquer V, Moore A, et al. Safety of Lebrikizumab in Adults and Adolescents with Moderate-to-Severe Atopic Dermatitis: An Integrated Analysis of Eight Clinical Trials. *Am J Clin Dermatol.* 2023 Jul 1;24(4):595–607.
9. Miron Y, Miller PE, Hughes C, Indersmitten T, Lerner EA, Cevikbas F. Mechanistic insights into the antipruritic effects of lebrikizumab, an anti-IL-13 mAb. *J Allergy Clin Immunol.* 2022 Sep;150(3):690–700.
10. Williams HC. Atopic Dermatitis. *N Engl J Med.* 2005;
11. Yew YW, Thyssen JP, Silverberg JI. A systematic review and meta-analysis of the regional and age-related differences in atopic dermatitis clinical characteristics. *J Am Acad Dermatol.* 2019 Feb;80(2):390–401.
12. Kim J, Kim BE, Leung DYM. Pathophysiology of atopic dermatitis: Clinical implications. *Allergy Asthma Proc.* 2019 Mar 1;40(2):84–92.
13. Bieber T. Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. *Allergy.* 2020 Jan;75(1):54–62.
14. Wallace DV. Treatment options for moderate to severe atopic dermatitis. *Allergy Asthma Proc.* 2022;43(6):474–93.
15. Coondoo A, Phiske M, Verma S, Lahiri K. Side-effects of topical steroids: A long overdue revisit. *Indian Dermatol Online J.* 2014;5(4):416.
16. Charman CR, Morris AD, Williams HC. Topical corticosteroid phobia in patients with atopic eczema: CORTICOSTEROID PHOBIA IN ATOPIC ECZEMA. *Br J Dermatol.* 2000 May;142(5):931–6.
17. Hewett, L. (2021) Leo Pharma announces FDA approval of Adbry™ (Tralokinumab-ldrm) as the first and only treatment specifically targeting IL-13 for adults with moderate-to-severe atopic dermatitis, National Eczema Association. Available at: <https://nationaleczema.org/blog/leo-122821/> (Accessed: 09 April 2024).
18. Zhao DJ, Huang LM, Xiao J, Chen L, Li X, Lin HX. Efficacy and safety of tralokinumab in the treatment of atopic dermatitis: A systematic review and meta-analysis of randomized controlled trials. *Medicine (Baltimore).* 2023 Aug 4;102(31):e34516.

19. Blauvelt A, Thyssen JP, Guttman-Yassky E, Bieber T, Serra-Baldrich E, Simpson E, Rosmarin D, Elmaraghy H, Meskimen E, Natalie CR, Liu Z. Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized double-blinded placebo-controlled phase III trials. *British Journal of Dermatology*. 2023 Jun;188(6):740-8.

20. Bernardo D, Bieber T, Torres T. Lebrikizumab for the treatment of moderate-to-severe atopic dermatitis. *American Journal of Clinical Dermatology*. 2023 Sep;24(5):753-64.

UNDER PEER REVIEW